Weave Bio
Category: AI in Healthcare
AI-native platform that automates and accelerates the drafting, reviewing, and submission of regulatory documents for the life sciences industry Weave Bio was founded in 2022. The company is led by Brandon Rice. Based in San Francisco, California. Team size: 37. Total funding raised: $36M total (all rounds). Latest round: Series A ($20M, October 2025). Key investors include USVP, Innovation Endeavors, Magnetic Ventures, Character, TMV, Serrado Capital.
- Founded
- 2022
- Headquarters
- San Francisco, California
- Team size
- 37
- Total funding
- $36M total (all rounds)
Value proposition
Reduce time and cost associated with preparing regulatory submissions by using AI to automate processes, enabling faster initiation of clinical trials and time-to-market
Products and solutions
Weave Platform (comprehensive regulatory lifecycle management), AutoIND (IND application automation), HAQ Manager (Health Authority Query management)
Unique value
AI-native platform purpose-built for regulatory submissions, combining automation with expert oversight to produce accurate, traceable, submission-ready content with proprietary knowledge graph encoding regulatory requirements
Target customer
Pharmaceutical and biotechnology companies of all sizes developing novel therapies that need to navigate regulatory submission processes
Industries served
Pharmaceuticals, Biotechnology, Life Sciences, CROs, Regulatory Consultants
Technology advantage
Claims to reduce IND preparation time by >50% via proprietary AI engine and knowledge graph that encodes regulatory requirements, enabling faster clinical trial starts and competitive time-to-market advantages
How they differentiate
Focused, AI-native automation specifically for regulatory submission workflows versus broader clinical/regulatory software suites offered by larger competitors; emphasizes speed, traceability, and submission readiness
Main competitors
Veeva Systems, IQVIA, Diligent Pharma
Key partnerships
Parexel (strategic partnership announced September 2025)
Notable customers
Parexel (via strategic partnership), Multiple unnamed pharmaceutical companies and biotech firms
Major milestones
Launched ReALM platform and AutoIND solution, Secured $20M Series A as part of $36M total funding, Reportedly earned a 2024 'BioTech AI Innovation Of The Year' award, Strategic partnership with Parexel, Commercial launch of HAQ Manager in November 2025
Growth metrics
Specific growth metrics (revenue, customer counts) are not publicly available
Market positioning
Positioned as an innovative challenger in regulatory technology for life sciences, targeting biopharma companies seeking to streamline IND and regulatory document preparation
Geographic focus
Primarily North America/USA (focus on FDA IND process); partnership with Parexel suggests intent for broader international reach
Patents and IP
Information on specific patents or IP is not publicly available
About Brandon Rice
Former Director of Product Management at Resilience (2020-2023), Director of Product at Synthego Corporation (2019-2020), with background in life science startups including drug manufacturing, discovery, diagnostics, CRISPR-based target identification and multi-omic cancer detection
Official website: https://www.weave.bio